102 related articles for article (PubMed ID: 29136675)
1. Only a Rapid Complete Biochemical Remission After 131I-Therapy is Associated with an Unimpaired Life Expectancy in Differentiated Thyroid Cancer.
Verburg FA; Mäder U; Grelle I; Giovanella L; Reiners C; Hänscheid H
Horm Metab Res; 2017 Nov; 49(11):860-868. PubMed ID: 29136675
[TBL] [Abstract][Full Text] [Related]
2. Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine.
Zhang X; Higuchi T; Tomonaga H; Lamid-Ochir O; Bhattarai A; Nguyen-Thu H; Taketomi-Takahashi A; Hirasawa H; Tsushima Y
Nucl Med Commun; 2020 Apr; 41(4):350-355. PubMed ID: 32032192
[TBL] [Abstract][Full Text] [Related]
3. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
[TBL] [Abstract][Full Text] [Related]
5. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.
Thies ED; Tanase K; Maeder U; Luster M; Buck AK; Hänscheid H; Reiners C; Verburg FA
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2281-90. PubMed ID: 25030619
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients.
Verburg FA; Mäder U; Reiners C; Hänscheid H
J Clin Endocrinol Metab; 2014 Dec; 99(12):4487-96. PubMed ID: 25259907
[TBL] [Abstract][Full Text] [Related]
7. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors.
Song HJ; Qiu ZL; Shen CT; Wei WJ; Luo QY
Eur J Endocrinol; 2015 Sep; 173(3):399-408. PubMed ID: 26104753
[TBL] [Abstract][Full Text] [Related]
9. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the usefulness of post-ablative and post-operative thyroglobulin concentration measuring in prognostic assessment of patients with differentiated thyroid cancer.
Gadawska-Juszczyk K; Kowalska A
Endokrynol Pol; 2015; 66(6):486-94. PubMed ID: 26662647
[TBL] [Abstract][Full Text] [Related]
11. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Ma C; Xie J; Kuang A
J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum midkine as a biomarker in differentiated thyroid cancer.
Meng Z; Tan J; Zhang G; Tian W; Fu Q; Li W; He X; Wu S; Yang Z; Liang X; Dong L; Zhang Q; Liu L; Zhang Y; Xu K; Liu B; Li N; Li X; Jia Q; He Y; Wang S; Wang R; Zheng W; Song X; Zhang J; Hu T; Liu N; Upadhyaya A
Life Sci; 2015 Jun; 130():18-24. PubMed ID: 25817231
[TBL] [Abstract][Full Text] [Related]
14. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
15. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
[TBL] [Abstract][Full Text] [Related]
16. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
[TBL] [Abstract][Full Text] [Related]
19. Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer.
Verburg FA; Mäder U; Luster M; Hänscheid H; Reiners C
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1390-8. PubMed ID: 26070546
[TBL] [Abstract][Full Text] [Related]
20. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival.
Piccardo A; Arecco F; Puntoni M; Foppiani L; Cabria M; Corvisieri S; Arlandini A; Altrinetti V; Bandelloni R; Orlandi F
Clin Nucl Med; 2013 Jan; 38(1):18-24. PubMed ID: 23242039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
